Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy?

Mehmet Zahid Kocak¹
Gulali Aktas¹
Tuba T. Duman¹
Burcin M. Atak¹
Haluk Savli¹

¹Abant Izzet Baysal University Hospital, Department of Internal Medicine, Bolu, Turkey.

http://dx.doi.org/10.1590/1806-9282.65.9.1156

INTRODUCTION
Diabetic renal disease is the most common cause of end-stage renal failure.¹ Experimental and clinical studies indicate that inflammation is a cardinal pathogenetic mechanism in diabetic nephropathy.²³ The elements of the diabetic environment (immune complexes, hyperglycemia, and advanced glycation end-products) stimulate kidney cells, causing the extricate of chemokines and regulation of cell adhesion molecules.⁴ These conditions facilitate renal infiltration by lymphocytes and monocytes in diabetic kidneys and the secretion of reactive oxygen products.⁴ During uric acid (UA) synthesis, oxidants are produced that can play a pivotal role in renal injury.⁵ It has been reported that free oxygen radicals driven by UA have important effects in endothelial dysfunction by inducing inflammation, which leads to the development of diabetic nephropathy.⁶ The relationship between UA and endothelial dysfunction, oxidative stress, nitric oxide activity, and smooth muscle cell proliferation has been reported.⁷⁸ Furthermore, it is still under investigation whether UA is an independent risk factor for macrovascular disease in diabetics.⁹

SUMMARY
OBJECTIVE: In this study, we aimed to analyze the relationship between serum uric acid (UA) and microalbuminuria as a marker of renal injury in type 2 diabetes mellitus.

METHODS: A total of 100 patients with type 2 diabetes mellitus were enrolled in the study. Participants were divided into two groups according to the urinary microalbumin/creatinine ratio: diabetic nephropathy and non-nephropathy group. UA and microalbuminuria were compared between the study groups.

RESULTS: Serum UA levels of diabetic nephropathy patients were significantly higher than those in the non-nephropathy group (UA in patients with diabetic nephropathy groups: 6.3 (1.82) mg/dl, UA in patients of the non-nephropathic group: 4.85 (1.92) mg/dl) (p<0.001). There was a correlation between microalbuminuria and UA (r=0.238). This correlation was statistically significant (p=0.017).

CONCLUSION: UA levels may be an important predictor of nephropathy in diabetic patients.


DATE OF SUBMISSION: 01-Apr-2019
DATE OF ACCEPTANCE: 02-May-2019
CORRESPONDING AUTHOR: Mehmet Zahid Kocak M.D.
Abant Izzet Baysal University Hospital, Department of Internal Medicine, 14280, Bolu, Turkey
Tel: +903742534656, Fax: +903742534615
E-mail: mehmetzahidkocak@hotmail.com
Microalbuminuria in subjects with type 2 diabetes mellitus is known to be a marker of the last phase in which renal injury can be reversed. We concluded that UA might be an easy and beneficial index of oxidative stress, and elevated UA might be a marker of renal injury. We aimed to study the association between microalbuminuria and serum UA levels as a marker of renal injury in diabetic patients.

**RESULTS**

A total of 100 subjects enrolled in the study. The nephropathy group had 36 (36%) patients, and the non-nephropathy 64 (64%). In the nephropathy group, 17 patients were women, and 19 were men. There were 34 women and 30 men in the non-nephropathy group (p=0.57). The mean age of the patients in the diabetic nephropathy and non-nephropathy groups were 62.4±7.6 and 59.3±9.3 years, respectively (p=0.1). There was no significant difference between WC, BMI, SBP, and DBP between the study groups (p>0.05 for all) (Table 1).

FBG was 225.5(62-466) mg/dl in the diabetic nephropathy group, and 135.5 (72-394) mg/dl in the non-nephropathy group (p<0.001). HbA1c was 9.6 (6.1-15.5) in the diabetic nephropathy group, and 6.9 (6.1-10.8) in the non-nephropathy group; there was a statistically significant difference between the groups.

**METHODS**

Our study was performed retrospectively after approval by the Ethics Committee of the Abant Izzet Baysal University Medical Faculty (Ethical approval number: 2018/196). A total of 100 patients with type 2 diabetes mellitus (51 female, 49 male) who were admitted to the internal medicine clinic between December 2017 and April 2018 were included. Participants were divided into groups according to the urinary microalbumin/creatinine ratio: diabetic nephropathy and non-nephropathy. Patients’ age, gender, waist circumference (WC), body mass index (BMI), duration of diabetes, systolic blood pressures (SBP), and diastolic blood pressures (DBP) were recorded. The UA, fasting blood glucose (FBG), total cholesterol, triglyceride, low-density protein (LDL), high-density lipoprotein (HDL), glycated hemoglobin (HbA1c), creatinine, urea, glomerular filtration rate (GFR), and microalbumin and creatinine in spot urine were recorded. Microalbuminuria was calculated using formula [spot urine microalbumin (gr/l)/spot urine creatinine g/dl] x 100. None of the patients had a history of gout and thiazide diuretics, and allopurinol users, malignant conditions, congenital disorders associated with elevated UA were not included in the study.

**Statistical analysis**

Statistical data were analyzed using SPSS software (SPSS 15.0 for Windows, IBM, Chicago, IL, USA). Descriptive statistics were presented as Median (min-max) and Mean ± SD. Normal distribution of continuous variables was evaluated by Kolmogorov-Smirnov tests. Homogeneous variables were analyzed using the Student t-test, and non-homogenously variables were analyzed using the Mann-Whitney U-test. The receiver operating characteristic (ROC) curve analyses were performed to determine UA cut-off values, the area under the curve (AUC), sensitivity, and specificity to predict diabetic nephropathy. Correlation analysis was conducted by Pearson correlation test. P<0.05 was accepted as statistically significant.

**TABLE 1. DEMOGRAPHIC CHARACTERISTICS AND LABORATORY DATA OF THE STUDY GROUP.**

<table>
<thead>
<tr>
<th></th>
<th>Diabetic nephropathy group</th>
<th>Diabetic non-nephropathy group</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>62.4±7.6</td>
<td>59.3±9.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Glomerular filtration rate (%)</td>
<td>73±20</td>
<td>83.8±15.5</td>
<td>0.003</td>
</tr>
<tr>
<td>Systolic Blood Pressure (mm/Hg)</td>
<td>130(120-180)</td>
<td>130 (100-180)</td>
<td>0.86</td>
</tr>
<tr>
<td>Diastolic Blood Pressure (mm/Hg)</td>
<td>80 (70-105)</td>
<td>80 (60-100)</td>
<td>0.41</td>
</tr>
<tr>
<td>Body Mass Index (kg/m2)</td>
<td>30.5(21.5-48.3)</td>
<td>30.3(22.3-49.3)</td>
<td>0.85</td>
</tr>
<tr>
<td>Waist Circumference (cm)</td>
<td>105.5(84-135)</td>
<td>103.5(77-144)</td>
<td>0.77</td>
</tr>
<tr>
<td>Uric acid (mg/dl)</td>
<td>6.3 (4.2-9.6)</td>
<td>4.9 (3-8.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hemoglobin A1C (%)</td>
<td>9.6 (6.1-15.5)</td>
<td>6.9 (6.1-10.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fasting Blood Glucose (mg/dl)</td>
<td>225.5(62-466)</td>
<td>135.5 (72-394)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Low-Density Lipoprotein (mg/dl)</td>
<td>106 (102-2599)</td>
<td>118 (90-189)</td>
<td>0.81</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>150 (59-600)</td>
<td>145 (46-615)</td>
<td>0.42</td>
</tr>
<tr>
<td>High Densit Lipoprotein (mg/dl)</td>
<td>41 (25-73)</td>
<td>46 (25-79)</td>
<td>0.011</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.92 (0.65-1.2)</td>
<td>0.83 (0.63-1.2)</td>
<td>0.009</td>
</tr>
<tr>
<td>Microalbuminuria (mg/g)</td>
<td>48.2(531.4-624)</td>
<td>10.7(3-29)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
IS URIC ACID ELEVATION A RANDOM FINDING OR A CAUSATIVE AGENT OF DIABETIC NEPHROPATHY?

The serum creatinine level was 0.92 (0.65-1.2) mg/dl in the diabetic nephropathy, and 0.83 (0.63-1.2) mg/dl in the non-nephropathy group (p=0.009); GFR was significantly higher in the diabetic nephropathy group (p=0.003) (Table 1). HDL-cholesterol was 41 (25-73) mg/dl in the nephropathy group, and 46 (25-79) mg/dl in the non-nephropathy group (p=0.003). There were no significant differences in triglyceride and LDL-cholesterol levels between the study groups (p=0.05 for all) (Table 1). The UA in patients in the diabetic nephropathy and non-nephropathy groups were 6.3 (4.2-9.6) mg/dl and 4.9 (3.8-5.5) mg/dl, respectively; this difference was statistically significant (p<0.001).

In the study group, the correlation between microalbuminuria and UA was examined. There was a correlation between microalbuminuria and UA (r=0.238). This correlation was statistically significant (p=0.017). A ROC curve analysis was used to determine HbA1C, FBG, and UA in detecting diabetic nephropathy. The best cut-off values for UA was 5.2 mg/dl (AUC=0.749, p<0.001) (Figure 1). According to ROC analysis, UA predicted diabetic nephropathy with 80.6% sensitivity and 64.1% specificity. ROC curve analysis of HbA1C and FBG are shown in Figure 1.

**DISCUSSION**

This study showed a relationship between diabetic nephropathy and UA. It was found that the microalbuminuria levels were also increased due to the oxidants formed by the increased UA level. Thus, in type 2 diabetic patients, the increased UA levels may be a marker for early detection of diabetic nephropathies, such as microalbuminuria.

Macrophages and T cells accumulate in the interstitium, in the initial phase of the diabetic nephropathy. These T cells and macrophages secrete proinflammatory cytokines such as tumor necrosis factor-a (TNF-a) and interleukin-1 (IL-1). Advanced glycation end-products and hyperglycemia stimulate chemokine production in renal cells. These increased chemokines then direct the migration of additional leukocytes to the kidneys and form an inflammatory cycle that causes renal damage. These events enable renal infiltration of lymphocytes and monocytes in the kidneys and facilitate the secretion of destructive molecules such as reactive oxygen products.

UA is produced by xanthine oxidase and is a product of purine degradation. While UA is synthesized, oxidants are produced that can cause renal dysfunction and cardiovascular disease. It has been reported that UA plays an important role in endothelial dysfunction by inducing inflammation with these oxygen-radical products and may lead to the development of diabetic nephropathy. Hyperuricemia-induced endothelial dysfunction has been suggested to reduce renal perfusion, along with glomerular hypertension and renal hypertrophy, by stimulating afferent vascular smooth muscle cell proliferation, which suggests that increased UA levels are a detrimental factor in the kidneys.

One study found that serum UA correlated significantly with diabetic nephropathy and that the serum UA level was found to be an important cause of nephropathy in diabetic patients. A study by Neupane et al. reported that serum UA levels match urinary albumin excretion. Another study showed a positive correlation between microalbuminuria and serum UA. Therefore, it was concluded that serum UA and microalbuminuria levels are early diagnostic markers for cardiovascular and renal diseases. In addition, it has been reported that it is very useful to identify the prognosis of the disease in diabetic patients. In our study, UA and microalbuminuria had weak correlations and were not statistically significant, whereas UA levels were statistically significantly higher in nephropathic patients.

Elevated serum UA is related to renal injury by glomerular hypertrophy and sclerosis, but there are controversial reports on the association between UA levels and chronic renal disease in the literature.
The independent role of mild hyperuricemia on the progression of renal disease is uncertain at present. Severe elevated serum UA levels have been found to be an independent risk factor for renal damage. Serum UA levels in our study were mildly elevated and associated with diabetic nephropathy.

Reactive oxygen radicals are formed during UA production, and it is reported that UA may be a simple and beneficial marker of increased oxidative stress. With the use of allopurinol, UA levels were reduced, as were the harmful effects of UA. With the decrease in UA levels, were also reported suppression of the aldosterone system of renin-angiotensin, increased nitric oxide, reduced oxidative stress, improved endothelial function, and decreased levels of markers for urinary inflammation.

Hyperuricemia is an individual risk factor for the development of chronic renal disease in patients with Type 2 diabetes and normal renal function. Most patients with type 2 diabetes mellitus have been found to have manifested renal glomerular and tubular damage even before the occurrence of microalbuminuria. Prevention or reduction of hyperuricemia in diabetic patients may prevent nephropathy progression.

Limitations of the present study are its retrospective design and relatively small study population. However, increased UA levels in diabetic nephropathy are important results that may contribute to the current literature.

**CONCLUSION**

The effect of elevated UA levels on renal damage is evident. In conclusion, UA elevation is not a random finding; it is correlated with microalbumin levels in patients with diabetic nephropathy. UA levels may be an important predictor of nephropathy in diabetic patients.

**REFERENCES**


